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with histomorphometric parameters such as bone volume fraction
(r = −0.89, p < 0.0001; r = −0.5, p < 0.007; respectively) and trabecular
number (r = −0.71, p < 0.0001; r = −0.38, p < 0.037; respectively).
Fig. 1. Coronal section of medial tibial plateau of saline injected knee (A).
The MIA-injected knee (B–D) shows loss of proteoglycan, chondrocyte
proliferation (B, arrow), chondrocyte cluster (B, arrow head), ﬁbrillation
(C, arrow), delamination, subchondral bone sclerosis, and ﬁbrotic bone
marrow (D, arrow).
Fig. 2. Coronal micro-CT images show osteophytes (A, arrow) and
cysts (C, asterisk) in the medial tibia of MIA-injected knee. Histology
sections conﬁrmed osteophyte (B, arrow) and cyst (D, asterisk) formation.
Note the presence of osteoblasts lining the areas of bone resorption
(D, arrow).
Conclusions: These ﬁndings demonstrate that the low-dose MIA rat
model closely mimics the pathological features of progressive human
OA such as cartilage degradation, subchondral bone sclerosis, cyst and
osteophyte formation. Moreover, this model demonstrates measurable
changes in both the cartilage and the subchondral bone. Monitoring
of low-dose MIA induced OA in rats using in vivo micro-CT enables
tracking of structural changes in the tibial subchondral bone for the
individual animal over time, and could be used to track changes in bone
in preclinical drug intervention studies for treatment of OA.
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Purpose: A homozygous recessive disorder in humans called Bardet-
Biedl Syndrome (BBS) results in primary cilia defects. BBS mutant
mice similarly exhibit ciliopathy related disorders. Chondrocytes are
known to contain primary cilia. Primary cilia have been shown to
play fundamental cellular roles. In the present study we analyzed the
temporomandibular (TM) and knee joints of BBS mutant mice as a
normal collagen chondrocyte speciﬁc animal model of osteoarthritis (OA)
in humans.
Methods: BBS mutant mice, and age-matched controls, were compared
histologically at 3, 6 and 12 months of age. Tissues were ﬁxed in
4% paraformaldehyde, processed to parafﬁn sections, stained with
Hemotoxylin, Safranin O and Fast Green, and analyzed using light
microscopy. Joint morphology was characterized and compared using
ImageJ (NIH; Bethesda, MD). Sections were stained for HtrA1 and DDR2.
Results: BBS mutant mice demonstrated evidence of OA including
articular cartilage (AC) ﬁssuring, thinning, decrease in proteoglycan
saturation with a concomitant increase in HtrA1 and DDR2. Chondrocytes
exhibited a propensity for clustering within the matrix. The extent of OA
related abnormalities was more pronounced in TM versus knee joints.
Conclusions: These results suggest a mechanism of early onset OA in TMJ
and knees of BBS mutant mice. The degradation pattern of the articular
cartilage, including up regulation of HtrA1 and DDR2, in the TMJ and
knees of BBS mutant mice follows the same recognized process that has
been observed in mutant collagen OA mouse models. The exacerbated
condition of the TMJ compared to knee might indicate that TMJ AC is
unique. The present study shows the relevance of the BBS homozygous
mouse as a viable alternative model for the human condition of OA.
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Background & Purpose: The mucopolysaccharidoses (MPS) are a group of
11 distinct inherited disorders due to mutations in the genes encoding
enzymes of glycosaminoglycan (GAG) degradation. Progressive and
severe bone and cartilage pathology are characteristic of these disorders.
Naturally occurring animal models have been described for several MPS,
with similarly severe cartilage and bone disease. The goal of this study
was to determine the inﬂammatory and cartilage/bone changes in the
rat model of MPS type VI (Maroteaux-Lamy disease), and to study of the
effects of anti-TNF-alpha drugs on the disease progression.
Methods: The age-progressive cartilage and bone disease in MPS VI
and control rats were studied by a variety of standard biochemical,
histological and clinical methods. MPS VI rats also were treated with the
anti-TNF-alpha drug, CTNO1081, and the effects on cartilage and bone
disease evaluated.
Results: The pathological and biochemical changes in the MPS VI
rats were very similar to those reported previously in patients
with arthritis and induced animal models of the disease. These
included elevation of various inﬂammatory markers, including TNF-
alpha, enhanced chondrocyte apoptosis, synovial hyperplasia, and
proteoglycan degradation. We therefore treated these animals with the
experimental anti-TNF-alpha drug, CTNO181. When initiated at 1 month
of age, intravenous treatment with CNTO1081 prevented the elevation
of TNF-alpha, RANKL and other inﬂammatory molecules, not only in the
blood, but also in articular chondrocytes and ﬁbroblast-like synoviocytes
(FLS). Treatment of 6 month-old animals also reduced the levels of these
molecules to normal. The number of apoptotic articular chondrocytes
in MPS VI rats was similarly reduced, with less inﬁltration of synovial
tissue into the underlying bone.
Conclusions: Many of the inﬂammatory and cartilage/chondrocyte
pathological changes that occurred in the MPS VI rats resembled those
